) GlobalCRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy product Partnership follows submission of the Clinical TrialApplication (CTA) to the MHRA.
ZIMA-101 is designed to assess the safety, tolerability, and preliminary clinical activity of ZI-MA4-1 in patients with advanced solid cancers, including lung cancer, ovarian cancer, head and neck cancer, and sarcomas ... About the ZIMA-101 trial..
About the ZIMA-101 trial. ... "This is an exciting moment, the submission of the CTA is a huge step towards bringing the ZIMA-101 study into the clinic, " said Prof ... for the ZIMA-101 trial.
It is the aim of Parties that several local subcontractors and suppliers will be involved in the supply chain of the New Plant,” said Miquel Zorita, CorporateDevelopment Director at Zima.
The year 2025 has been transformational for the Defense Department... Air force drops Biden-era reoptimization efforts ... Meanwhile, Air ForceSecretaryTroy Meink said some of the most sweeping reorganization efforts would be too disruptive. Join us Jan ... .